Hims & Hers rises on partnership with Novo Nordisk to sell Wegovy on its platform
Shares of Hims & Hers HIMS.N rise 43% to $40.73 premarket
Novo Nordisk NOVOb.CO has partnered with the telehealth firm to sell its popular weight loss drug through a bundled offering on HIMS platform
Starting this week, customers will get access to the offerings of all dose strengths of Wegovy and a membership at a price starting at $599 per month - HIMS
HIMS says it will continue to offer personalized compounded versions of semaglutide, the active ingredient in Novo's Wegovy
Earlier this month, HIMS said it plans to sell Eli Lilly's LLY.N Zepbound on its platform
Up to last close, HIMS up 17.8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








